An Anti-Inflammatory Sterol Decreases Obesity-Related Inflammation-Induced Insulin Resistance and Metabolic Dysregulation

Table 4

HE3286-0401 treatment effects in obese inflamed subgroups.

Group	Effect	Value	Change		P	Test^g
			HE3286	Placebo
Cohort 1; MCP > 40^a	ΔHOMA2 IR^c	Day 84 mean	−0.1	+0.4	0.02
	ΔC-peptide		−0.03	+0.1	0.04
	ΔHb		−0.25	+0.06	0.02	t-test
	ΔHct		−0.06	+0.09	0.02
	ΔRBC		−0.05	+0.09	0.02
	ΔnHbA1c	Day 84 median	−0.34		0.03	Wilcoxon
		Day 84 median		0.1	—
		Day 84 numbers	17⇓^e 5⇑^f	9⇓ 16⇑	0.0008	Fisher’s Exact
		Day 84 mean	−0.46	−0.21	—
		Day 84 mean; −2 outliers^d	−0.82	−0.21	0.04	t-test
Cohort 2; BMI > 31^b	ΔnHbA1c	Day 112 mean	−1.0		0.0007
				−0.3	—	t-test
			−1.0	−0.3	0.03
		Day 112 median	−1.2		0.002	Wilcoxon
				−0.16	—
			−1.2	−0.16	0.02	Mann Whitney

^aParticipants with baseline monocyte chemoattractant protein greater than the lowest tertile (40 pmol/L). ^bParticipants with baseline body mass index greater than the median (31 kg/m²). ^cΔ: change in; HOMA2 IR: homeostatic assessment model insulin resistance; Hb: hemoglobin; Hct: hematocrit, RBC: red blood cells; nHbA1c: normalized HbA1c (see Section 2 for details); ^dTwo outliers removed (outliers circled in Figure 4(c), Mahalanobis distance); ^eDecrease from zero change; ^fIncrease from zero change; ^gParametric means and t-test used for data with normally distributed data, Nonparametric medians, Wilcoxon, Mann Whitney, and Fisher’s Exact test used for abnormally distributed data.